{"commentary":{"count":6,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":false},"name":"ZEAL-1L","nct_id":"NCT04475939","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=zeal-1l-nct04475939. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"ZEAL-1L","arms":[{"description":"Eligible participants will receive niraparib along with pembrolizumab.","label":"Participants receiving niraparib plus pembrolizumab","type":"EXPERIMENTAL"},{"description":"Eligible participants will receive matching placebo along with pembrolizumab.","label":"Participants receiving placebo plus pembrolizumab","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-03-23","type":"ACTUAL"},"conditions":["Lung Cancer, Non-Small Cell"],"enrollment":{"count":666,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Niraparib","type":"DRUG"},{"name":"Pembrolizumab","type":"BIOLOGICAL"},{"name":"Placebo","type":"DRUG"}],"last_update":"2026-06-18","lead_sponsor":"GlaxoSmithKline","official_title":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum -Based Chemotherapy With Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung Cancer (ZEAL-1L)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2025-02-26","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) - Complete and Partial Response (CR/PR) Population","timeFrame":"Up to 52 months"}],"references":[{"citation":"Ramalingam SS, Velcheti V, Altan M, de Castro G Jr, Thomas M, Sanborn RE, Mazieres J, Schuler M, Isaksson J, Schenker M, Poddubskaya E, Kim YJ, Parakh S, Liu W, Neibauer MW, Aghera V, Chiu G, Peters S. Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L). J Thorac Oncol. 2026 Jul 10:104087. doi: 10.1016/j.jtho.2026.104087. Online ahead of print.","pmid":"42431263","type":"DERIVED"},{"citation":"Ramalingam SS, Thara E, Awad MM, Dowlati A, Haque B, Stinchcombe TE, Dy GK, Spigel DR, Lu S, Iyer Singh N, Tang Y, Teslenko I, Iannotti N. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer. 2022 Jan 1;128(1):65-74. doi: 10.1002/cncr.33885. Epub 2021 Sep 3.","pmid":"34478166","type":"DERIVED"}],"start_date":{"date":"2020-10-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer","url":"https://clinicaltrials.gov/study/NCT04475939"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/zeal-1l-nct04475939"}